{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:57:31Z","timestamp":1790621851230,"version":"4.1.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006312","name":"BrightFocus Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rainwater Foundation Tau Consortium"},{"DOI":"10.13039\/100003607","name":"Association for Frontotemporal Degeneration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003607","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Cure Alzheimer's Foundation"},{"name":"The Tau SILK Consortium"},{"name":"Anonymous Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Alzheimer disease (AD) was once a clinical diagnosis confirmed by postmortem autopsy. Today, with the development of AD biomarkers, laboratory assays to detect AD pathology are able to complement clinical diagnosis in symptomatic individuals with uncertain diagnosis. A variety of commercially available assays are performed as laboratory-developed tests, and many more are in development for both clinical and research purposes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Content<\/jats:title><jats:p>The role of laboratory medicine in diagnosing and managing AD is expanding; thus, it is important for laboratory professionals and ordering physicians to understand the strengths and limitations of both existing and emerging AD biomarker assays. In this review, we will provide an overview of the diagnosis of AD, discuss existing laboratory assays for AD and their recommended use, and examine the clinical performance of emerging AD biomarkers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>The field of AD biomarker discovery and assay development is rapidly evolving, with recent studies promising to improve both the diagnosis of symptomatic individuals and enrollment and monitoring of asymptomatic individuals in research studies. However, care must be taken to ensure proper use and interpretation of these assays. For clinical purposes, these assays are meant to aid in diagnosis but are not themselves diagnostic. For individuals without symptoms, AD biomarker tests are still only appropriate for research purposes. Additionally, there are analytical challenges that require careful attention, especially for longitudinal use of AD tests.<\/jats:p><\/jats:sec>","DOI":"10.1373\/jalm.2019.030080","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T23:45:13Z","timestamp":1576539913000},"page":"194-208","source":"Crossref","is-referenced-by-count":53,"title":["Biomarkers of Alzheimer Disease"],"prefix":"10.1093","volume":"5","author":[{"given":"Melissa M","family":"Budelier","sequence":"first","affiliation":[{"name":"Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall J","family":"Bateman","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,30]]},"reference":[{"key":"2020010518582046200_B1","unstructured":"Alzheimer's Association. Earlier diagnosis. https:\/\/www.alz.org\/alzheimers-dementia\/research_progress\/earlier-diagnosis (Accessed June 2019)."},{"key":"2020010518582046200_B2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"2020010518582046200_B3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"2020010518582046200_B4","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jalz.2018.07.220","article-title":"Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease","volume":"14","author":"Shaw","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2020010518582046200_B5","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"key":"2020010518582046200_B6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jalz.2019.01.010","article-title":"2019 Alzheimer's disease facts and figures","volume":"15","year":"2019","journal-title":"Alzheimers Dement"},{"key":"2020010518582046200_B7","unstructured":"Alzheimer's Association. 2019 Alzheimer's disease facts and figures. https:\/\/www.alz.org\/media\/documents\/alzheimers-facts-and-figures-2019-r.pdf (Accessed June 2019)."},{"key":"2020010518582046200_B8","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(96)10203-8","article-title":"Auguste D and Alzheimer's disease","volume":"349","author":"Maurer","year":"1997","journal-title":"Lancet"},{"key":"2020010518582046200_B9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"2020010518582046200_B10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"},{"key":"2020010518582046200_B11","unstructured":"Fujirebio Diagnostics. Fujirebio Diagnostics receives FDA breakthrough device designation for Lumipulse\u00ae G \u0392-amyloid ratio (1-42\/1-40) quantitative in vitro diagnostic test. https:\/\/www.fujirebio-us.com\/media-and-events\/news\/2019\/fujirebio-diagnostics-receives-fda-breakthrough-device-designation (Accessed June 2019)."},{"key":"2020010518582046200_B12","unstructured":"Roche Diagnostics. FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease. https:\/\/www.roche.com\/dam\/jcr:4cae6bb1-7b58-492d-91c9-994afcdd29dd\/de\/20180720-MR_DIA_AAIC_en.pdf (Accessed June 2019)."},{"key":"2020010518582046200_B13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/JAD-160298","article-title":"Performance evaluation of an automated ELISA system for Alzheimer's disease detection in clinical routine","volume":"54","author":"Chiasserini","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"2020010518582046200_B14","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archneurol.2011.105","article-title":"Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1\u201342, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology","volume":"68","author":"Fagan","year":"2011","journal-title":"Arch Neurol"},{"key":"2020010518582046200_B15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/acn3.274","article-title":"CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: better diagnostic markers of Alzheimer disease","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"2020010518582046200_B16","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jalz.2018.01.013","article-title":"Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging","volume":"14","author":"Schindler","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2020010518582046200_B17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.dadm.2018.08.006","article-title":"Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: the ABIDE project","volume":"10","author":"Willemse","year":"2018","journal-title":"Alzheimers Dement (Amst)"},{"key":"2020010518582046200_B18","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/acn3.50873","article-title":"Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse","volume":"6","author":"Alcolea","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"2020010518582046200_B19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.clinbiochem.2019.05.006","article-title":"Method comparison study of the Elecsys(R) beta-Amyloid (1-42) CSF assay versus comparator assays and LC-MS\/MS","volume":"72","author":"Shaw","year":"2019","journal-title":"Clin Biochem"},{"key":"2020010518582046200_B20","first-page":"986310","article-title":"Confounding factors influencing amyloid beta concentration in cerebrospinal fluid","volume":"2010","author":"Bjerke","year":"2010","journal-title":"Int J Alzheimers Dis"},{"key":"2020010518582046200_B21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3233\/JAD-132489","article-title":"Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta(4)(2) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry","volume":"41","author":"Korecka","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"2020010518582046200_B22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1373\/clinchem.2013.220392","article-title":"Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid","volume":"60","author":"Leinenbach","year":"2014","journal-title":"Clin Chem"},{"key":"2020010518582046200_B23","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/jnc.13838","article-title":"Reference measurement procedure for CSF amyloid beta (A\u03b2)1-42 and the CSF A\u03b21\u201342\/A\u03b21-40 ratio\u2014a cross-validation study against amyloid PET","volume":"139","author":"Pannee","year":"2016","journal-title":"J Neurochemistry"},{"key":"2020010518582046200_B24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1177\/2211068214559979","article-title":"Biomarkers in the diagnosis and prognosis of Alzheimer's disease","volume":"20","author":"Schaffer","year":"2015","journal-title":"J Lab Autom"},{"key":"2020010518582046200_B25","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/nan.12378","article-title":"Review: tau in biofluids\u2014relation to pathology, imaging and clinical features","volume":"43","author":"Zetterberg","year":"2017","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2020010518582046200_B26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clinbiochem.2019.05.005","article-title":"Elecsys\u00ae Total-Tau and Phospho-Tau (181P) CSF assays: analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid","volume":"72","author":"Lifke","year":"2019","journal-title":"Clin Biochem"},{"key":"2020010518582046200_B27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","article-title":"Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease","volume":"61","author":"Hampel","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"2020010518582046200_B28","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3233\/JAD-180548","article-title":"Clinical experience with cerebrospinal fluid abeta42, total and phosphorylated tau in the evaluation of 1,016 individuals for suspected dementia","volume":"65","author":"Tariciotti","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"2020010518582046200_B29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fnagi.2019.00121","article-title":"Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer's disease","volume":"11","author":"Barthelemy","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"2020010518582046200_B30","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","article-title":"Tau kinetics in neurons and the human central nervous system","volume":"97","author":"Sato","year":"2018","journal-title":"Neuron"},{"key":"2020010518582046200_B31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jalz.2018.09.010","article-title":"Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease","volume":"15","author":"Chen","year":"2019","journal-title":"Alzheimers Dement"},{"key":"2020010518582046200_B32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1373\/clinchem.2013.216515","article-title":"Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry","volume":"60","author":"McAvoy","year":"2014","journal-title":"Clin Chem"},{"key":"2020010518582046200_B33","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"key":"2020010518582046200_B34","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","article-title":"Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease","volume":"278","author":"Farrer","year":"1997","journal-title":"JAMA"},{"key":"2020010518582046200_B35","unstructured":"Athena Diagnostics. ADmark Alzheimer's evaluation. https:\/\/www.athenadiagnostics.com\/view-full-catalog\/a\/admark-reg;-alzheimer-s-evaluation (Accessed June 2019)."},{"key":"2020010518582046200_B36","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High precision plasma amyloid-\u03b2 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"key":"2020010518582046200_B37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-beta biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"2020010518582046200_B38","doi-asserted-by":"crossref","first-page":"27204","DOI":"10.1074\/jbc.M116.721779","article-title":"Human central nervous system (CNS) ApoE isoforms are increased by age, differentially altered by amyloidosis, and relative amounts reversed in the CNS compared with plasma","volume":"291","author":"Baker-Nigh","year":"2016","journal-title":"J Biol Chem"},{"key":"2020010518582046200_B39","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2183\/pjab.93.048","article-title":"The past, present, and future of disease-modifying therapies for Alzheimer's disease","volume":"93","author":"Suzuki","year":"2017","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"2020010518582046200_B40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt59","article-title":"Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease","volume":"3","author":"Bateman","year":"2011","journal-title":"Alzheimers Res Ther"},{"key":"2020010518582046200_B41","doi-asserted-by":"crossref","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology"},{"key":"2020010518582046200_B42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40120-017-0073-9","article-title":"A review of fluid biomarkers for Alzheimer's disease: moving from CSF to blood","volume":"6","author":"Blennow","year":"2017","journal-title":"Neurol Ther"},{"key":"2020010518582046200_B43","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","article-title":"Current state of Alzheimer's fluid biomarkers","volume":"136","author":"Molinuevo","year":"2018","journal-title":"Acta Neuropathol"},{"key":"2020010518582046200_B44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13041-019-0448-1","article-title":"Blood-based molecular biomarkers for Alzheimer's disease","volume":"12","author":"Zetterberg","year":"2019","journal-title":"Mol Brain"},{"key":"2020010518582046200_B45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/archneur.57.1.100","article-title":"Plasma and cerebrospinal fluid levels of amyloid proteins 1\u201340 and 1\u201342 in Alzheimer disease","volume":"57","author":"Mehta","year":"2000","journal-title":"Arch Neurol"},{"key":"2020010518582046200_B46","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3233\/JAD-2011-101977","article-title":"Meta-analysis of plasma amyloid-beta levels in Alzheimer's disease","volume":"26","author":"Song","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"2020010518582046200_B47","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.dadm.2017.07.004","article-title":"Plasma amyloid beta 42\/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals","volume":"8","author":"Fandos","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"key":"2020010518582046200_B48","doi-asserted-by":"publisher","article-title":"Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status","author":"Palmqvist","DOI":"10.1001\/jamaneurol.2019.1632"},{"key":"2020010518582046200_B49","first-page":"169","article-title":"Plasma biomarkers of AD emerging as essential tools for drug development: an EU\/US CTAD Task Force report","volume":"6","author":"Bateman","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"key":"2020010518582046200_B50","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","article-title":"Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic","volume":"14","author":"Hampel","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"2020010518582046200_B51","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jalz.2018.05.008","article-title":"The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: a review","volume":"10","author":"Hansson","year":"2018","journal-title":"Alzheimer's Dement"},{"key":"2020010518582046200_B52","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3233\/JAD-170773","article-title":"The past and the future of Alzheimer's disease fluid biomarkers","volume":"62","author":"Blennow","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"2020010518582046200_B53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13024-017-0206-8","article-title":"Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome","volume":"12","author":"Tatebe","year":"2017","journal-title":"Mol Neurodegener"},{"key":"2020010518582046200_B54","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2020010518582046200_B55","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","article-title":"Plasma tau in Alzheimer disease","volume":"87","author":"Mattson","year":"2016","journal-title":"Neurology"},{"key":"2020010518582046200_B56","doi-asserted-by":"crossref","first-page":"a018309","DOI":"10.1101\/cshperspect.a018309","article-title":"Neurofilaments and neurofilament proteins in health and disease","volume":"9","author":"Yuan","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2020010518582046200_B57","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1212\/WNL.0000000000007767","article-title":"Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures","volume":"93","author":"Mielke","year":"2019","journal-title":"Neurology"},{"key":"2020010518582046200_B58","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaneurol.2018.3746","article-title":"Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders","volume":"76","author":"Olsson","year":"2019","journal-title":"JAMA Neurol"},{"key":"2020010518582046200_B59","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol"},{"key":"2020010518582046200_B60","doi-asserted-by":"crossref","first-page":"17368","DOI":"10.1038\/s41598-018-35766-w","article-title":"Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease","volume":"8","author":"Lin","year":"2018","journal-title":"Sci Rep"},{"key":"2020010518582046200_B61","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13195-018-0404-9","article-title":"Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease","volume":"10","author":"Lewczuk","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"2020010518582046200_B62","doi-asserted-by":"crossref","first-page":"382107","DOI":"10.1155\/2012\/382107","article-title":"Neurofilament phosphorylation during development and disease: which came first, the phosphorylation or the accumulation?","volume":"2012","author":"Dale","year":"2012","journal-title":"J Amino Acids"},{"key":"2020010518582046200_B63","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jalm\/article-pdf\/5\/1\/194\/31709248\/jalm.2019.030080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jalm\/article-pdf\/5\/1\/194\/31709248\/jalm.2019.030080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T17:13:49Z","timestamp":1665249229000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/5\/1\/194\/5690025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,30]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12,30]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1373\/jalm.2019.030080","relation":{},"ISSN":["2576-9456","2475-7241"],"issn-type":[{"value":"2576-9456","type":"print"},{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2019,12,30]]}}}